On October 1, 2019, the Court of Chancery rendered an opinion in In re Clovis Oncology, Inc. Derivative Litigation, denying a motion to dismiss a Caremark claim for breach of fiduciary duty and reinforcing a director’s duty...more
10/15/2019
/ Board of Directors ,
Breach of Duty ,
CFOs ,
Clinical Trials ,
Compliance ,
Corporate Governance ,
Directors ,
Duty of Loyalty ,
Fiduciary Duty ,
Food and Drug Administration (FDA) ,
Motion to Dismiss ,
Oversight Duties ,
Prescription Drugs